JE
MCID: JPN002
MIFTS: 55

Japanese Encephalitis (JE) malady

Categories: Rare diseases, Infectious diseases, Neuronal diseases

Aliases & Classifications for Japanese Encephalitis

Aliases & Descriptions for Japanese Encephalitis:

Name: Japanese Encephalitis 12 50 56 3 3 14 69
Je 50 3
Japanese B Encephalitis 12
Encephalitis, Japanese 42
Encephalitis Japanese 52

Characteristics:

Orphanet epidemiological data:

56
japanese encephalitis
Inheritance: Not applicable; Age of onset: All ages; Age of death: any age;

Classifications:



External Ids:

Disease Ontology 12 DOID:10844
ICD10 33 A83.0
ICD9CM 35 062.0
MeSH 42 D004672
NCIt 47 C34577
Orphanet 56 ORPHA79139
MESH via Orphanet 43 D004672
UMLS via Orphanet 70 C0014057
ICD10 via Orphanet 34 A83.0
UMLS 69 C0014057

Summaries for Japanese Encephalitis

CDC : 3 Japanese encephalitis (JE) virus is the leading cause of vaccine-preventable encephalitis in Asia and the western Pacific. For most travelers to Asia, the risk for JE is very low but varies based on destination, duration of travel, season, and activities. JE virus is maintained in a cycle involving mosquitoes and vertebrate hosts, mainly pigs and wading birds. Humans can be infected when bitten by an infected mosquito. Most human infections are asymptomatic or result in only mild symptoms. However, a small percentage of infected persons develop inflammation of the brain (encephalitis), with symptoms including sudden onset of headache, high fever, disorientation, coma, tremors and convulsions. About 1 in 4 cases are fatal. There is no specific treatment for JE. Patient management focuses on supportive care and management of complications. Steps to prevent JE include using personal protective measures to prevent mosquito bites and vaccination.

MalaCards based summary : Japanese Encephalitis, also known as je, is related to hepatitis c virus and encephalitis, and has symptoms including headache, high fever and neck stiffness. An important gene associated with Japanese Encephalitis is CD209 (CD209 Molecule), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Ethanol and Vaccines have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and b cells, and related phenotypes are hematopoietic system and homeostasis/metabolism

Disease Ontology : 12 A viral infectious disease that results_in infection located in brain, has material basis in Japanese encephalitis virus, which is transmitted_by Culex tritaeniorhynchus mosquito bite. The infection has symptom headache, has symptom high fever, has symptom neck stiffness, has symptom stupor, has symptom disorientation, has symptom coma, has symptom tremors, has symptom convulsions, and has symptom spastic paralysis.

Wikipedia : 71 Japanese encephalitis (JE), formerly known as Japanese B encephalitis to distinguish it from Economo\'s... more...

Related Diseases for Japanese Encephalitis

Diseases related to Japanese Encephalitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 89)
id Related Disease Score Top Affiliating Genes
1 hepatitis c virus 28.7 CD209 CLEC4M DDX58 HELLS TLR3
2 encephalitis 10.9
3 west nile virus 10.1
4 hypercementosis 10.1 CCL5 IFNB1
5 esophagus leiomyoma 10.1 IFNB1 STAT1
6 vogt-koyanagi-harada disease 10.0 CXCL10 TNF
7 parovarian cyst 10.0 CD209 IFNB1 TNF
8 vps11-related autosomal recessive hypomyelinating leukodystrophy 10.0 CCL5 TNF
9 primary optic atrophy 10.0 CCL5 CXCL10
10 methylmalonic aciduria and homocystinuria, cblj type 10.0 IFNB1 STAT1
11 streptococcal meningitis 10.0 IFNB1 TLR3
12 cauda equina syndrome 10.0 IFNB1 TNF
13 central nervous system angiosarcoma 10.0 CXCL10 DDX58 TNF
14 osteodysplasty precocious of danks mayne and kozlowski 9.9 CCL5 TNF
15 vestibule of mouth cancer 9.9 TLR3 TNF
16 neuronitis 9.9
17 steroid dehydrogenase deficiency dental anomalies 9.9 CCL5 TNF
18 anus leiomyosarcoma 9.9 CCL5 CD209 TNF
19 endometrial transitional cell carcinoma 9.9 CD209 STAT1 TNF
20 argentine hemorrhagic fever 9.9 CD209 CXCL10 TLR3
21 neonatal jaundice 9.9 CCL5 IFNB1 TNF
22 murray valley encephalitis 9.9
23 pulpitis 9.9 CCL5 CXCL10 TNF
24 bladder signet ring cell adenocarcinoma 9.9 CCL5 CXCL10 TNF
25 status epilepticus 9.9 CCL5 CXCL10 TNF
26 mineral metabolism disease 9.8 CCL5 CD209 DDX58 TNF
27 upper gum cancer 9.8 CD209 DDX58 IFNB1 TLR3
28 neuroblastoma 9.8
29 malaria 9.8
30 endotheliitis 9.8
31 tick-borne encephalitis 9.8
32 yellow fever 9.8
33 complex regional pain syndrome 9.7 CCL5 CXCL10 IFNB1 TNF
34 advanced sleep phase syndrome, familial, 1 9.7 CCL5 CXCL10 IFNB1 TNF
35 viral encephalitis 9.7
36 depressed scar 9.7 CD209 STAT1 TLR3 TNF
37 hemorrhagic fever 9.6
38 cerebritis 9.6
39 herpes simplex encephalitis 9.6
40 medulloblastoma 9.6
41 transverse myelitis 9.6
42 hemiplegia 9.6
43 encephalopathy 9.6
44 rabies 9.6
45 dengue hemorrhagic fever 9.6
46 acute transverse myelitis 9.6
47 herpes simplex 9.6
48 meningitis 9.6
49 chikungunya 9.6
50 filariasis 9.6

Graphical network of the top 20 diseases related to Japanese Encephalitis:



Diseases related to Japanese Encephalitis

Symptoms & Phenotypes for Japanese Encephalitis

Symptoms:

12
  • headache
  • high fever
  • neck stiffness
  • stupor
  • disorientation
  • coma
  • tremors
  • convulsions
  • spastic paralysis

MGI Mouse Phenotypes related to Japanese Encephalitis:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.96 IFNB1 STAT1 TLR3 TNF CCL5 CLEC4G
2 homeostasis/metabolism MP:0005376 9.81 CLEC4G CLEC4M CXCL10 DDX58 HELLS IFNB1
3 immune system MP:0005387 9.65 CCL5 CLEC4G CLEC4M CXCL10 DDX58 HELLS
4 neoplasm MP:0002006 9.02 DDX58 IFNB1 STAT1 TLR3 TNF

Drugs & Therapeutics for Japanese Encephalitis

Drugs for Japanese Encephalitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 19)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4 64-17-5 702
2 Vaccines Phase 4,Phase 3,Phase 2,Phase 1
3 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1
4 Antibodies Phase 4,Phase 3,Phase 2,Phase 1
5
Aluminum hydroxide Approved Phase 3,Phase 1 21645-51-2
6 DEET Phase 3
7 Protective Agents Phase 3
8 Insect Repellents Phase 3
9
Lactitol Phase 3 585-86-4 3871
10 Heptavalent Pneumococcal Conjugate Vaccine Phase 3
11 Pharmaceutical Solutions Phase 3
12
Ribavirin Approved Phase 2 36791-04-5 37542
13 Anti-Infective Agents Phase 2
14 Antimetabolites Phase 2
15 Antiviral Agents Phase 2
16 gamma-Globulins Phase 2
17 Immunoglobulins, Intravenous Phase 2
18 Rho(D) Immune Globulin Phase 2
19 Aluminum sulfate Phase 1

Interventional clinical trials:

(show top 50) (show all 77)
id Name Status NCT ID Phase
1 Antibody Response of a Boosted Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Unknown status NCT01954810 Phase 4
2 Cellular and Humoral Immunity in Elderly After Immunization With a Japanese Encephalitis Vaccine Unknown status NCT01398540 Phase 4
3 A Prospective, Open Label Study of Human T Cell Responses to Live Attenuated Japanese Encephalitis Vaccine SA14-14-2 Completed NCT01656200 Phase 4
4 Long-term Immunogenicity and Safety of Fourth Administration of Boryung Cell-Culture Japanese Encephalitis Vaccineinj Completed NCT02532569 Phase 4
5 Immunogenicity of Co-administration of Measles and Japanese Encephalitis Vaccines Completed NCT02643433 Phase 4
6 Immunogenicity of a Live Attenuated Chimeric JE Vaccine (IMOJEV) as a Booster Dose in Thai Children Primed With CD.JEVAX Completed NCT02526550 Phase 4
7 Long-term Immunogenicity After Receipt of JE Vaccine and Antibody Response and Safety to a Booster Dose Completed NCT02514746 Phase 4
8 This is a Study to Assess the Safety and Immunogenicity of Ixiaro® (IC51) in an Elderly Population Completed NCT01158599 Phase 4
9 Post-licensure Safety Study of IMOJEV® in Thailand Completed NCT01981967 Phase 4
10 6-year Antibody Check After Third Vaccination Against Japanese Encephalitis Completed NCT02039440 Phase 4
11 Lot-to-lot Consistency Trial of JE Live Attenuated SA 14-14-2 Vaccine Completed NCT01567865 Phase 4
12 Immunogenicity of SA 14-14-2 JE Vaccine Completed NCT01635816 Phase 4
13 Immunogenicity and Safety of Live Attenuated Varicella Vaccine Combined With Live Attenuated JE Vaccine Completed NCT01815073 Phase 4
14 Postmarketing Surveillance Study for IMOJEV® in Republic of Korea Recruiting NCT02933710 Phase 4
15 Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella Vaccine Recruiting NCT02880865 Phase 4
16 Clinical Evaluation of Insect Repellent and Insecticide Treated Nets in Lao PDR Unknown status NCT00938379 Phase 3
17 Study of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV™) Compared to CD.JEVAX™ in Toddlers Completed NCT01396512 Phase 3
18 A Study of Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine in Infants and Toddlers Completed NCT01092507 Phase 3
19 Determining Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles Vaccine Completed NCT00249769 Phase 3
20 Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51 Completed NCT00596102 Phase 3
21 Long-term Follow-up of Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine in Toddlers Completed NCT01001988 Phase 3
22 Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV Completed NCT01190228 Phase 3
23 Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers Completed NCT01188343 Phase 3
24 Live Attenuated Japanese Encephalitis (JE) Vaccine Coadministered With Measles Vaccine in Infants 9 Months of Age Completed NCT00463684 Phase 3
25 Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51 Completed NCT00595790 Phase 3
26 Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51 Completed NCT00595270 Phase 3
27 Immunogenicity Study of the Japanese Encephalitis Vaccine IC51 Completed NCT00604708 Phase 3
28 Boosterability of Live Attenuated Japanese Encephalitis (JE) Vaccine in Children Who Have Previously Received Inactivated JE Vaccine Completed NCT00463476 Phase 3
29 Ixiaro as Booster After Mouse-brain Derived Vaccines for Japanese Encephalitis Completed NCT01386827 Phase 3
30 Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy Subjects Completed NCT02492165 Phase 3
31 Safety and Tolerability of the Japanese Encephalitis Vaccine IC51 Completed NCT00605085 Phase 3
32 Determining Long-Term Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles Vaccine Completed NCT00412516 Phase 3
33 Study of ChimeriVax™-Japanese Encephalitis Vaccine in Toddlers in Thailand and the Philippines Completed NCT00735644 Phase 3
34 Immunogenicity and Safety of Inactivated Vero Cell Derived Japanese Encephalitis Vaccine in Thai Children Completed NCT01408537 Phase 3
35 Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult Subjects Completed NCT01662440 Phase 3
36 A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAX Completed NCT00314145 Phase 3
37 Comparison of Three Commercial Batches of the Japanese Encephalitis Vaccine IC51 Completed NCT00595465 Phase 3
38 A Clinical Trial for Inactivated Japanese Encephalitis Vaccine in Healthy Chinese Infants Completed NCT02367664 Phase 3
39 Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51 Completed NCT00594958 Phase 3
40 Study of a Booster Dose of IMOJEV® Vaccine One Year After Primary Immunization in Healthy Children in South Korea Completed NCT01900444 Phase 3
41 Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population Completed NCT01041573 Phase 3
42 Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440 Completed NCT00596271 Phase 3
43 Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis. Completed NCT00314132 Phase 3
44 Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic Country Completed NCT01296360 Phase 3
45 Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51 Completed NCT00595309 Phase 3
46 Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling Completed NCT00776230 Phase 3
47 Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries Completed NCT01047839 Phase 3
48 Clinical Trial to Assess the Immunogenicity and Safety of the Vero Cell-derived JE Vaccine in Korea Completed NCT01150942 Phase 3
49 Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study Completed NCT01246479 Phase 3
50 A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults Completed NCT01466387 Phase 3

Search NIH Clinical Center for Japanese Encephalitis

Cochrane evidence based reviews: encephalitis, japanese

Genetic Tests for Japanese Encephalitis

Anatomical Context for Japanese Encephalitis

MalaCards organs/tissues related to Japanese Encephalitis:

39
Brain, T Cells, B Cells, Testes, Endothelial, Kidney, Monocytes

The Foundational Model of Anatomy Ontology organs/tissues related to Japanese Encephalitis:

18
Brain

Publications for Japanese Encephalitis

Articles related to Japanese Encephalitis:

(show top 50) (show all 672)
id Title Authors Year
1
Autochthonous Japanese Encephalitis with Yellow Fever Coinfection in Africa. ( 28402771 )
2017
2
Introducing a cleavable signal peptide enhances the packaging efficiency of lentiviral vectors pseudotyped with Japanese encephalitis virus envelope proteins. ( 27993624 )
2017
3
Antisense Oligonucleotides Targeting Raf-1 Block Japanese Encephalitis Virus In Vitro and In Vivo. ( 28051352 )
2017
4
Immunogenicity of a Live Attenuated Chimeric Japanese Encephalitis Vaccine as a Booster Dose After Primary Vaccination With Live Attenuated SA14-14-2 Vaccine: A Phase IV Study in Thai Children. ( 27846060 )
2017
5
European Aedes albopictus and Culex pipiens are Competent Vectors for Japanese Encephalitis Virus. ( 28085881 )
2017
6
How Zoophilic Japanese Encephalitis Vector Mosquitoes Feed on Humans. ( 28082626 )
2017
7
Dual infection with Japanese encephalitis and dengue fever: Issues with diagnosis. ( 28084252 )
2017
8
Mx Is Not Responsible for the Antiviral Activity of Interferon-I+ against Japanese Encephalitis Virus. ( 28075421 )
2017
9
Post-licensure, phase IV, safety study of a live attenuated Japanese encephalitis recombinant vaccine in children in Thailand. ( 27903416 )
2017
10
GRP78 is an important host-factor for Japanese encephalitis virus entry and replication in mammalian cells. ( 28053106 )
2017
11
Interactions of human microglia cells with Japanese encephalitis virus. ( 28088249 )
2017
12
Diagnostic dilemma-dengue or Japanese encephalitis? ( 28084251 )
2017
13
Inhibition of Japanese encephalitis virus (JEV) replication by specific RNA aptamer against JEV methyltransferase. ( 27986564 )
2017
14
MicroRNA-33a-5p Modulates Japanese Encephalitis Virus Replication by Targeting Eukaryotic Translation Elongation Factor 1A1. ( 26819305 )
2016
15
Sphingomyelin generated by sphingomyelin synthase 1 is involved in attachment and infection with Japanese encephalitis virus. ( 27892528 )
2016
16
Production of Japanese Encephalitis Virus-Like Particles Using Insect Cell Expression Systems. ( 27076311 )
2016
17
Immunogenicity and safety of the inactivated Japanese encephalitis vaccine IXIAROAr in elderly subjects: Open-label, uncontrolled, multi-center, phase 4 study. ( 27460550 )
2016
18
CCR5 ameliorates Japanese encephalitis via dictating the equilibrium of regulatory CD4(+)Foxp3(+) T and IL-17(+)CD4(+) Th17 cells. ( 27439902 )
2016
19
Can we differentiate between herpes simplex encephalitis and Japanese encephalitis? ( 27288787 )
2016
20
The ubiquitin-proteasome system is essential for the productive entry of Japanese encephalitis virus. ( 27567260 )
2016
21
Apraxia of eyelid closure in a case of post-Japanese encephalitis Parkinsonism. ( 27147166 )
2016
22
A simple method for developing an infectious cDNA clone of Japanese encephalitis virus. ( 27665292 )
2016
23
Pharmacodynamics of aminoglycosides and tetracycline derivatives against Japanese encephalitis virus. ( 26972394 )
2016
24
A large outbreak of Japanese encephalitis predominantly among adults in northern region of West Bengal, India. ( 27096294 )
2016
25
A collaborative study of an alternative in vitro potency assay for the Japanese encephalitis vaccine. ( 27497622 )
2016
26
Tumor suppressor p53 functions as an essential antiviral molecule against Japanese encephalitis virus. ( 27956051 )
2016
27
Sublingual immunization with Japanese encephalitis virus vaccines induces effective immunity through both cellular and humoral immune responses in mice. ( 28004418 )
2016
28
The Spatio-temporal Distribution of Japanese Encephalitis Cases in Different Age Groups in Mainland China, 2004 - 2014. ( 27050414 )
2016
29
A tropical menace of co-infection of Japanese encephalitis and neurocysticercosis in two children. ( 27606026 )
2016
30
Corrigendum to "Epidemiology of Japanese encephalitis in South Korea, 2007-2010". ( 27167063 )
2016
31
Low Protective Efficacy of the Current Japanese Encephalitis Vaccine against the Emerging Genotype 5 Japanese Encephalitis Virus. ( 27139722 )
2016
32
Japanese Encephalitis Virus Infection Results in Transient Dysfunction of Memory Learning and Cholinesterase Inhibition. ( 27447805 )
2016
33
Characterization of codon usage pattern and influencing factors in Japanese Encephalitis Virus. ( 27189042 )
2016
34
Pre-cut Filter Paper for Detecting Anti-Japanese Encephalitis Virus IgM from Dried Cerebrospinal Fluid Spots. ( 26986061 )
2016
35
A Centralized Report on Pediatric Japanese Encephalitis Cases from Beijing Children's Hospital, 2013. ( 28081752 )
2016
36
Immunogenicity of a Japanese encephalitis chimeric virus vaccine as a booster dose after primary vaccination with SA14-14-2 vaccine in Thai children. ( 27628323 )
2016
37
Impaired Japanese encephalitis virus replication in p62/SQSTM1 deficient mouse embryonic fibroblasts. ( 27624873 )
2016
38
Transcriptional regulation of miR-15b by c-Rel and CREB in Japanese encephalitis virus infection. ( 26931521 )
2016
39
Complete Genome Sequence of a Genotype III Japanese Encephalitis Virus, Isolated from Pigs in Sichuan, China. ( 27932640 )
2016
40
Comparison of the live-attenuated Japanese Encephalitis vaccine SA14-14-2 strain with Its pre-attenuated virulent parent SA14 strain: Similarities and differences in vitro and in vivo. ( 27498826 )
2016
41
Antiviral activity of luteolin against Japanese encephalitis virus. ( 27126774 )
2016
42
Integrin I+vI^3 promotes infection by Japanese encephalitis virus. ( 28043010 )
2016
43
DC-SIGN as an attachment factor mediates Japanese encephalitis virus infection of human dendritic cells via interaction with a single high-mannose residue of viral E glycoprotein. ( 26629951 )
2016
44
The NS3 and NS4A genes as the targets of RNA interference inhibit replication of Japanese encephalitis virus in vitro and in vivo. ( 27593564 )
2016
45
Japanese Encephalitis. ( 27450609 )
2016
46
Argonaute 2 Suppresses the Infection of Japanese Encephalitis Virus in Aedes aegypti. ( 27169949 )
2016
47
One-year immunogenicity kinetics and safety of a purified chick embryo cell rabies vaccine and an inactivated Vero cell-derived Japanese encephalitis vaccine administered concomitantly according to a new, 1-week, accelerated primary series. ( 26994987 )
2016
48
Serological evidence of widespread West Nile virus and Japanese encephalitis virus infection in native domestic ducks (Anas platyrhynchos var domesticus) in Kuttanad region, Kerala, India. ( 27638121 )
2016
49
Phylogenetic analysis reveals that Japanese encephalitis virus genotype III is still prevalent in swine herds in Sichuan province in China. ( 26976139 )
2016
50
Transmembrane Domains of NS2B Contribute to Both Viral RNA Replication and Particle Formation in Japanese Encephalitis Virus. ( 27053551 )
2016

Variations for Japanese Encephalitis

Expression for Japanese Encephalitis

Search GEO for disease gene expression data for Japanese Encephalitis.

Pathways for Japanese Encephalitis

Pathways related to Japanese Encephalitis according to GeneCards Suite gene sharing:

(show all 24)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.8 CCL5 CD209 CXCL10 DDX58 IFNB1 STAT1
2
Show member pathways
13.11 CCL5 CXCL10 DDX58 IFNB1 STAT1 TNF
3
Show member pathways
12.72 CCL5 CD209 IFNB1 STAT1 TLR3 TNF
4
Show member pathways
12.52 CCL5 CXCL10 DDX58 IFNB1 TNF
5
Show member pathways
12.28 CCL5 CXCL10 DDX58 IFNB1 STAT1 TLR3
6 12.23 CCL5 CXCL10 DDX58 STAT1 TLR3 TNF
7
Show member pathways
12.07 IFNB1 TLR3 TNF
8
Show member pathways
12.06 STAT1 TLR3 TNF
9 11.98 STAT1 TLR3 TNF
10
Show member pathways
11.98 CXCL10 IFNB1 STAT1 TNF
11 11.97 CD209 CLEC4M IFNB1 STAT1 TNF
12
Show member pathways
11.97 CCL5 CD209 CLEC4M CXCL10 DDX58 IFNB1
13
Show member pathways
11.95 IFNB1 STAT1 TNF
14 11.84 IFNB1 STAT1 TNF
15 11.76 CCL5 CXCL10 TNF
16
Show member pathways
11.74 STAT1 TLR3 TNF
17 11.67 DDX58 IFNB1 STAT1 TLR3 TNF
18 11.57 CD209 IFNB1 TNF
19 11.36 CCL5 CXCL10 TNF
20 11.18 CXCL10 IFNB1 STAT1
21 11.09 IFNB1 TNF
22 11.01 CCL5 CXCL10 TNF
23
Show member pathways
10.94 DDX58 STAT1
24 10.92 CCL5 IFNB1 TNF

GO Terms for Japanese Encephalitis

Biological processes related to Japanese Encephalitis according to GeneCards Suite gene sharing:

(show all 40)
id Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 9.96 CD209 CLEC4M DDX58 TLR3
2 immune system process GO:0002376 9.94 CD209 CLEC4M DDX58 TLR3
3 inflammatory response GO:0006954 9.92 CCL5 CXCL10 TLR3 TNF
4 defense response to bacterium GO:0042742 9.86 IFNB1 TLR3 TNF
5 adaptive immune response GO:0002250 9.85 CD209 CLEC4M IFNB1
6 viral process GO:0016032 9.83 CD209 CLEC4G CLEC4M DDX58 STAT1
7 viral entry into host cell GO:0046718 9.77 CD209 CLEC4G CLEC4M
8 positive regulation of smooth muscle cell proliferation GO:0048661 9.72 CCL5 STAT1 TNF
9 positive regulation of interleukin-6 production GO:0032755 9.69 DDX58 TLR3 TNF
10 protein kinase B signaling GO:0043491 9.68 CCL5 TNF
11 lipopolysaccharide-mediated signaling pathway GO:0031663 9.68 CCL5 TNF
12 regulation of type I interferon-mediated signaling pathway GO:0060338 9.67 IFNB1 STAT1
13 positive regulation of cytokine production GO:0001819 9.67 TLR3 TNF
14 defense response GO:0006952 9.67 CXCL10 IFNB1 TLR3 TNF
15 negative regulation of endothelial cell proliferation GO:0001937 9.66 STAT1 TNF
16 positive regulation of interferon-beta production GO:0032728 9.66 DDX58 TLR3
17 positive regulation of NF-kappaB import into nucleus GO:0042346 9.65 TLR3 TNF
18 negative regulation of myoblast differentiation GO:0045662 9.65 CXCL10 TNF
19 positive regulation of innate immune response GO:0045089 9.64 CCL5 IFNB1
20 positive regulation of monocyte chemotaxis GO:0090026 9.63 CCL5 CXCL10
21 positive regulation of chemokine production GO:0032722 9.63 TLR3 TNF
22 negative regulation of viral genome replication GO:0045071 9.63 CCL5 IFNB1 TNF
23 viral genome replication GO:0019079 9.62 CD209 CLEC4M
24 positive regulation of T cell migration GO:2000406 9.61 CCL5 CXCL10
25 cellular response to exogenous dsRNA GO:0071360 9.61 IFNB1 TLR3
26 positive regulation of chemokine biosynthetic process GO:0045080 9.6 TLR3 TNF
27 modulation by virus of host morphology or physiology GO:0019048 9.58 CD209 CLEC4M
28 necroptotic signaling pathway GO:0097527 9.58 TLR3 TNF
29 response to exogenous dsRNA GO:0043330 9.58 DDX58 IFNB1 TLR3
30 cellular response to dsRNA GO:0071359 9.57 IFNB1 TLR3
31 cell-cell recognition GO:0009988 9.56 CD209 CLEC4M
32 detection of virus GO:0009597 9.52 DDX58 TLR3
33 positive regulation of interleukin-8 production GO:0032757 9.5 DDX58 TLR3 TNF
34 virion attachment to host cell GO:0019062 9.49 CD209 CLEC4M
35 peptide antigen transport GO:0046968 9.48 CD209 CLEC4M
36 leukocyte cell-cell adhesion GO:0007159 9.43 CCL5 CD209 CLEC4M
37 defense response to virus GO:0051607 9.35 CXCL10 DDX58 IFNB1 STAT1 TLR3
38 cellular response to interferon-beta GO:0035458 9.33 IFNB1 STAT1 TLR3
39 response to virus GO:0009615 9.1 CCL5 CXCL10 DDX58 IFNB1 TLR3 TNF
40 positive regulation of transcription from RNA polymerase II promoter GO:0045944 10.01 CXCL10 DDX58 IFNB1 STAT1 TLR3 TNF

Molecular functions related to Japanese Encephalitis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 carbohydrate binding GO:0030246 9.58 CD209 CLEC4G CLEC4M
2 tumor necrosis factor receptor binding GO:0005164 9.37 STAT1 TNF
3 peptide antigen binding GO:0042605 9.32 CD209 CLEC4M
4 mannose binding GO:0005537 9.26 CD209 CLEC4M
5 virion binding GO:0046790 9.16 CD209 CLEC4M
6 virus receptor activity GO:0001618 9.13 CD209 CLEC4G CLEC4M
7 cytokine activity GO:0005125 8.92 CCL5 CXCL10 IFNB1 TNF

Sources for Japanese Encephalitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....